行情

ONCE

Spark
ONCE
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
-53.8400
62.17
12.64
4,375,090,499.58
关于 ONCE
Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
展开

ONCE 新闻

更多
FDA OKs two companion diagnostics for Lynparza for prostate cancer
The FDA approves Myriad Genetics' (NASDAQ:MYGN) BRACAnalysis CDx test and Roche (OTCQX:RHHBY) unit Foundation Medicine's FoundationOne CDx test for use as
seekingalpha · 5天前
FDA OKs Roche's Tecentriq for certain lung cancer patients in first-line setting
The FDA approves Roche (OTCQX:RHHBY -0.9%) unit Genentech's Tecentriq (atezolizumab) for the first-line treatment of adults with metastatic non-small cell
seekingalpha · 6天前
Passage Bio's IPO tops out at $248.4M after options exercised
American City Business Journals · 03/11 16:35
GAMCO Investors Exits Viacom, Spark Therapeutics
GuruFocus.com · 02/28 15:33
科技巨头为什么要被拆分?其他玩家给出了6大依据
猎云网 · 01/26 00:37
B站向武汉捐赠1000万元专项资金及超30万元防护物资
IT之家 · 01/26 00:07
阿里采购医疗物资驰援武汉
经济日报 · 01/25 22:04
利比亚石油出口遭打击 6天损失近2.566亿美元
央视 · 01/25 22:03

热门股票

代码
价格
涨跌幅

微牛提供Spark(NASDAQ-ONCE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ONCE股票新闻,以帮助您做出投资决策。